May 17, 2020

Nokia look at how blockchain will transform the management of health data

healthcare services
Technology
Nokia
Blockchain
Catherine Sturman
2 min
blockchain
In a bid to give patients greater control over the management of their healthcare, Nokia are looking at ways in which blockchain can make this a reality...

In a bid to give patients greater control over the management of their healthcare, Nokia are looking at ways in which blockchain can make this a reality. A recent blog has highlighted the company’s ambitions to bring a multitude of advantages to patients and provide a system which is not only secure, but enable the development of a new global healthcare platform, transforming the traditional industry.

Undertaking a pilot with Finnish company OP Financial Group, Nokia will work “to explore new opportunities in the rising field of Digital Health, with the aim of giving people more control over their personal health data – how it is shared, who can access it, and how it can be used – with a focus on privacy and security offered by blockchain technologies.”

Similarly to platforms such as WhatsApp, the technology will have encryption embedded to enable enhanced security, and guarantee that the information which is being received is from an authenticated device.

Related stories

Incorporating 100 participants, the new pilot programme will see users utilise Nokia wearable devices and build a number of healthcare models. Rewards will be automatically applied by OP towards users who reach their fitness goals.

Kristian Luoma, Head of OP Lab at OP Financial Group, said: “We’re excited about the collaboration with Nokia. It is great to see Blockchain applied to something that needs trust, like in this our pilot we’re joining forces. This pilot is quite literally a prime example of the technologies we’ll use in the future, combined innovatively to create value.”

Through developing innovative technologies and services, Nokia will continue to provide devices to connect with local communities and build bespoke, exceptional health solutions for its users.

Share article

Jun 23, 2021

Introducing Dosis - the AI powered dosing platform

AI
medication
personalisedmedicine
chronicdisease
3 min
Dosis is an AI-powered personalised medication dosing platform that's on a mission to transform chronic disease management

Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works. 

When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing. 

The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced. 

What is the Strategic Anemia Advisor? 
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease. 

SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool. 

What else is Dosis working on? 
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs. 

What are Dosis' strategic goals for the next 2-3 years? 
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.

What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.

Share article